Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-19-351 from the NIH Guide for Grants and Contracts. The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding

Related Links:

Authors: Diaz JH Abstract Red meat allergies have followed tick bites on every continent except Antarctica. The sensitizing antigen is galactose-α-1,3-galactose (α-gal), an oligosaccharide constituent of nonprimate blood and meat, acquired by ticks during animal bloodfeeding. Because red meat allergy after tick bites is a worldwide phenomenon, the objectives of this review were to describe the global epidemiology of red meat allergy after tick bites and its immunological mechanisms; to identify the human risk factors for red meat allergy after tick bites; to identify the most common tick vectors of red ...
Source: Southern Medical Journal - Category: General Medicine Tags: South Med J Source Type: research
Additionally, side effects were more common among participants in the HCQ group than the placebo group. One expert says the results raise the question of whether some ongoing trials should stop.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
The vast majority of people with a penicillin allergy label are, in fact, not allergic, leading to significant healthcare implications. Experts say it is now time for a national “de-labelling” drive to help conserve vital antibiotics.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
An analysis of hospital admissions data by  The Pharmaceutical Journal shows that between 2012/2013 and 2018/2019, the number of hospital admissions in England where the patient had a diagnostic ‘label’ of penicillin allergy almost doubled, from 575,000 to 1.1 million.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Publication date: Available online 3 June 2020Source: Journal of Hospital InfectionAuthor(s): Neil Powell, Kate Honeyford, Jonathan Sandoe
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research
Publication date: Available online 3 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Clémence David, Marie Jachiet, Marc Pineton de Chambrun, Anne Sophie Gamez, Anas Mehdaoui, Thierry Zenone, Delphine Gobert, Achille Aouba, Anne Peterschmitt, Sylvain Palat, François Lifermann, Daniel Blockmans, Séverine Feuillet-Soummer, Luc Mouthon, Benjamin Terrier, French Vasculitis Study Group
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 2 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Matthew Greenhawt, Edwin H. Kim, Dianne E. Campbell, Todd D. Green, Romain Lambert, David M. Fleischer
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 2 June 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Jaya Muneswarao, Mohamed Azmi Hassali, Baharudin Ibrahim, Bandana Saini, Irfhan Ali Hyder Ali, Anees ur Rehman, Ashutosh Kumar Verma, Atta Abbas Naqvi, Rabia Hussain
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
More News: Allergy | Allergy & Immunology | Clinical Trials | Contracts | Funding | Grants | Infectious Diseases | Research | Study